Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Middle East Conflict Impacts Australia and New Zealand Businesses 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Royal Philips (AS: PHG) reaffirmed its full-year 2026 guidance after reporting stronger-than-expected first-quarter results, driven by solid sales growth, improving profit margins, and continued productivity gains despite tariff pressures and rising costs.
The Dutch health technology company posted Q1 2026 group sales of €3.90 billion, slightly above analyst expectations of €3.88 billion. Comparable sales increased 4%, outperforming the market consensus of 3.4%. Philips also reported an adjusted EBITA margin of 9%, ahead of analyst estimates of 8.4%, reflecting operational improvements and cost-saving initiatives.
CEO Roy Jakobs said Philips delivered a strong start to the year with healthy order growth and disciplined execution in a challenging macroeconomic environment. Comparable order intake rose 6%, supported by strong demand in the Diagnosis & Treatment and Connected Care divisions, particularly in North America and Europe.
Philips’ Personal Health segment delivered the best performance during the quarter, with comparable sales growth of 9%, significantly above analyst forecasts. The division’s adjusted EBITA margin climbed to 15.8%, also exceeding expectations.
The Diagnosis & Treatment business recorded 2% comparable sales growth, slightly below forecasts, but profitability improved sharply with an adjusted EBITA margin of 9.8%. Meanwhile, Connected Care remained the weakest segment, posting a 3% sales increase but suffering margin pressure from tariffs and inflation, resulting in a lower-than-expected 2.9% adjusted EBITA margin.
Income from operations rose to €241 million, while operating cash flow reached €188 million. Free cash flow totaled €28 million during the quarter.
Philips maintained its full-year 2026 outlook, forecasting comparable sales growth between 3% and 4.5%, adjusted EBITA margin of 12.5% to 13%, and free cash flow ranging from €1.30 billion to €1.50 billion.
The company also announced plans to repurchase up to 4 million shares worth approximately €91 million to support long-term incentive programs, with completion expected by the fourth quarter of 2028.
